Cyclerion Therapeutics, Inc. reported a net loss of $3.5 million for the fiscal year ending December 31, 2025, compared to a loss of $3.1 million in the previous year. The company generated total revenues of $2.1 million, a slight increase of 4% from $2 million in 2024. This revenue was primarily driven by a $1 million milestone payment from Akebia Therapeutics related to the initiation of Phase 2 clinical trials for praliciguat, as well as $800,000 from a purchase agreement with Akebia for additional development materials. However, revenue from the license agreement with Akebia decreased by 43% to $1 million, reflecting the company's ongoing challenges in monetizing its product pipeline.
Research and development expenses surged to $959,000 in 2025, a significant increase of 235% from $286,000 in 2024. This rise was attributed to heightened consulting costs associated with the development of CYC-126, an individualized therapy for treatment-resistant depression (TRD). General and administrative expenses also rose by 14% to $6.1 million, driven by increased professional consulting and legal fees. The overall increase in expenses contributed to a loss from operations of $4.97 million, a 37% increase compared to the previous year.
Strategically, Cyclerion has focused on advancing its TRD program, particularly through its collaboration with the Massachusetts Institute of Technology (MIT) and a partnership with Medsteer SAS. The MIT License Agreement, established in September 2025, allows Cyclerion to develop products using MIT's technology, with potential milestone payments totaling $4.4 million. The collaboration with Medsteer, initiated in January 2026, aims to leverage technology for anesthetic delivery and monitoring, with milestone payments of up to $3.7 million.
As of December 31, 2025, Cyclerion had approximately $3.2 million in cash and cash equivalents, which management believes will sustain operations through mid-2026. However, the company faces substantial doubt regarding its ability to continue as a going concern without raising additional capital. Cyclerion plans to seek further funding through equity or other financing transactions to support its ongoing development efforts and operational needs.
Looking ahead, Cyclerion aims to initiate a Phase 2 proof-of-concept study for CYC-126 in Australia in the second half of 2026, with U.S. enrollment expected to begin in early 2027. The company is also exploring additional opportunities related to its legacy soluble guanylate cyclase (sGC) stimulator assets, while continuing to evaluate potential collaborations and licensing agreements to enhance shareholder value.
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics focuses on developing novel therapeutics for neuropsychiatric and serious diseases, primarily targeting treatment-resistant depression (TRD). The company leverages its legacy soluble guanylate cyclase (sGC) assets through licensing and out-licensing agreements, aiming to generate revenue for pipeline development. It emphasizes intellectual property protection, regulatory compliance, and strategic partnerships to advance innovative treatments in high unmet medical needs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.